Zhou Bo, Zhang Shi-Ran, Chen Geng
Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Oncol Lett. 2025 Jun 3;30(2):382. doi: 10.3892/ol.2025.15128. eCollection 2025 Aug.
Gallbladder cancer (GBC) is a highly lethal disease and the most common cancer of the biliary tract. Numerous patients are diagnosed at an advanced stage, limiting surgical options and necessitating local or systemic treatment. Despite advancements in cancer treatment, 5-year survival rates remain low. Various therapeutic methods are available for the treatment of advanced GBC, including local therapy, chemoradiotherapy, immunotherapy and targeted therapy. Although these treatments offer hope and broader prospects for patients, challenges persist. Through a systematic review of the literature from PubMed and Web of Science over the past decade, a summary and analysis of treatment trends, existing challenges and the latest research developments in advanced GBC were provided.
胆囊癌(GBC)是一种致死率很高的疾病,也是最常见的胆道癌症。许多患者在晚期才被诊断出来,这限制了手术选择,因此需要进行局部或全身治疗。尽管癌症治疗取得了进展,但5年生存率仍然很低。晚期GBC的治疗有多种方法可供选择,包括局部治疗、放化疗、免疫治疗和靶向治疗。虽然这些治疗方法为患者带来了希望和更广阔的前景,但挑战依然存在。通过对过去十年PubMed和Web of Science文献的系统回顾,对晚期GBC的治疗趋势、现存挑战和最新研究进展进行了总结与分析。